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Background: Hepatic steatosis is a major concern in living donor liver transplantation. Factors affecting
hepatic functional status after a donor right hepatectomy (with the middle hepatic vein included in the
graft) with a focus on changes owing to steatosis were retrospectively studied.
Methods: Donors (n = 325) were categorized into three groups: G0 (no steatosis, n = 178), G1 (< = 10%
steatosis, n = 128) and G2 (>10% steatosis, n = 19). Donors with >20% steatosis were excluded. Changes
in aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin levels and prothrombin time
(PT) were assessed. Factors predicting steatosis were also assessed. A liver biopsy was performed on
selected donors.
Results: The ALT level rose until day 3 in G1 and day 6 in G2 (P < 0.05). The AST level rose until day 7
in G2 (P < 0.05) but stayed unchanged in G1. The bilirubin level was higher only on day 1 in G2 (P < 0.05).
By day 30, no significant difference between any groups was noted. Receiver-operating characteristic
(ROC) area under the curve for body mass index (BMI) on predicting steatosis was 0.75 [confidence
interval (CI) = 69–80]. Among donors with a BMI > 23.5 kg/m2, 75% had steatosis. Five donors had >20%
steatosis and were not assessed.
Conclusion: Using a liver with up to 20% steatosis in right liver donation, even if the middle hepatic vein
is included in the graft, is safe. For Asian donors, a BMI > 23.5 kg/m2 is a guide in deciding whether to
perform a liver biopsy for steatosis.
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Introduction
Owing to the severe scarcity of deceased-donor organs for trans-
plantation in the region, living donors supply most of the liver
grafts for transplantation in Asia.1 Apart from technical complex-
ity, donor safety is a key issue in living donor liver transplantation.
Appropriate donor selection optimizes both donor safety and
recipient outcomes. Hepatic macrosteatosis is common in the
general public and has been reported to have a prevalence of
around 30%.2,3 Poor initial graft function, poor overall graft sur-
vival and other complications have been reported with the use of
steatotic grafts in living donor liver transplantation as well as
deceased donor liver transplantation.4–6 Therefore, most centres,
including the present, limit the acceptance of liver donors with
hepatic steatosis up to 20%.7 Assessment of the degree of steatosis
is an important part of donor evaluation. It was reported that
recipients of steatotic liver grafts had transient deterioration of
results of liver function tests.8,9 To date, very few authors have
focused on the issue of post-operative change in liver enzymes
after a donor hepatectomy.8,9 In the present study, the patterns of
changes in the results of liver function tests of a cohort of donors
who underwent a right-liver donor hepatectomy were studied
and factors analyzed predicting steatosis in them. Hopefully, the
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results of the present study may be useful in the selection and
post-operative management of liver donors.
Patients and methods
The present study covered the period from 1999 to 2009. Three
hundred and twenty-five donors who underwent a donor right
hepatectomy with the middle hepatic vein (MHV) included in the
graft were the subjects of the study. All potential donors had to
undergo intensive workup for donor selection. A detailed descrip-
tion has been given elsewhere.10 In summary, a basic medical
history of a potential donor was assessed to exclude any contrain-
dication to donor surgery. If there was no contraindication, the
possible candidate was then subjected to a blood test, radiological
assessment and psychological evaluation.
Evaluation of donors with suspected steatosis
Potential donors with hyperlipidaemia, deranged liver enzymes
and a body mass index (BMI) of 27 or above were suspected of
having a fatty liver. Results from ultrasonography and computed
tomography were also considered. In the absence of other poten-
tial donors, these high-risk candidates were further evaluated. A
biopsy was performed in 21 selected candidates after considering
the results of the initial assessment on an individual basis. The
maximum degree of steatosis accepted for liver donation was 20%.
All recipients underwent an intra-operative core biopsy of the
graft before wound closure. The core of the tissue was examined
under haematoxylin and eosin stain.
For the present study, only macrovesicular steatosis was consid-
ered significant. The donors were categorized into three groups
according to the degree of macrovesicular steatosis: the first group
(G0) had no steatosis (n = 178, 54.77%), the second group (G1)
had up to 10% steatosis (n = 128, 39.38%) and the third group
(G2) had more than 10% and up to 30% steatosis (n = 19, 5.85%).
In G2, five donors had more than 20% steatosis, which was
detected in a routine post-transplant biopsy.
Hepatectomy and post-operative care
All donors underwent a right hepatectomy with the MHV
included. A hepatic parenchymal dissection was done with a
Cavitron Ultrasonic Surgical Aspirator (Valleylab, Boulder,
Colorado, USA). The abdomen was closed without any drains.
The initial post-operative care took place in the intensive care unit
(ICU). The donors were transferred to the general ward on post-
operative day 1 if there were no adverse events. Daily biochemical
assessment of liver functions and blood count were performed.
The donors were discharged upon stabilization of clinical status
and followed up in the outpatient clinic initially weekly and sub-
sequently with a decreasing frequency. In each follow-up session,
a liver function test and blood count were performed.
The three groups (G0, G1 and G2) were compared in terms
of serum aspartate aminotransferase (AST) level, serum alanine
aminotransferase (ALT) level, total serum bilirubin level and pro-
thrombin time (PT) before surgery and on post-operative day 1 to
day 7 and day 30. The upper limit of the reference value was set
at 28 u/l for AST, 31 u/l for ALT and 19 mmol/l for bilirubin. The
baseline parameters of the three groups are shown in Table 1.
Statistical analysis
Values were presented as medians with range. Comparison analy-
sis was performed using the Kruskal–Wallis test and the Mann–
Whitney U-test for continuous variables and the chi-squared test
for categorical variables. A logistic regression model was used in
the analysis to detect risk factors. A P-value below 0.05 stood for
statistical significance. SPSS software Version 15.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis.
Results
When the three groups were compared (Table 1), there was a
significant increase in donor weight (P < 0.001), BMI (P = 0.001),
graft weight (P < 0.001), blood loss (P = 0.003), ICU stay (P =
0.03), ALT level (P < 0.001) and operating time (P = 0.001) with
Table 1 Baseline parameters of the three groups of steatosis
No steatosis < = 10% steatosis >10% steatosis Pa
(n = 178) (n = 128) (n = 19)
Age (years) 34 (18–58) 34.5 (18–58) 41 (22–47) 0.09
Body weight (kg) 52 (41–74) 60 (39–95) 63.5 (43.5–84) <0.001
BMI (kg/m2) 20.26 (16.5–29) 22.7 (16–32) 24.4 (18–28.6) 0.001
Remnant left liver (%) 36 (23.6–49.5) 34.6 (26–47.7) 33.5 (26–42) 0.001
Graft weight (g) 565 (320–890) 637.5 (390–1020) 670 (550–1140) <0.001
Blood loss (cc) 318.5 (42–1600) 373 (80–1400) 545 (240–1000) 0.003
Post-operative ICU stay (days) 1 (0–4) 1 (0–5) 2 (1–8) 0.03
Post-operative hospital stay (days) 7 (4–30) 7 (4–22) 9 (5–38) 0.12
Total operation time (min) 437.5 (260–810) 470.5 (310–870) 525 (355–932) 0.001
aKruskal–Wallis test.
BMI, body mass index; ICU, intensive care unit.
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the increasing degree of steatosis. However, there were no signifi-
cant differences in donor age and pre-operative AST and bilirubin
levels between the groups.
Change in the ALT level
The pattern of change in the median ALT level is shown in Fig. 1.
The peak level was noted in post-operative day 1 in all groups. G1
showed a significant difference until day 3. In G2, the difference
lasted until day 6 when compared with G0. By day 30, 72% of the
donors in G0, 65% in G1 and 63% in G2 had an ALT level above
the reference range, showing no significant difference (P = 0.36).
Change in the AST level
The peak median AST level was noted in post-operative day 1 in
all groups (Fig. 2). G1 did not show a significant difference after
surgery when compared with G0. G2 had a significant difference
until day 7. By day 30, 83% of the donors in G0, 77% in G1 and
82% in G2 had a AST level above the reference range (P = 0.5).
Change in the bilirubin level
The rise in bilirubin was slower and peaked on day 3 in all groups
(Fig. 3). A significant difference was noted only in G2 by day 1. By
day 30, 27% of the donors in G0, 16% in G1 and 26% in G2 had
bilirubin levels above the reference range (P = 0.12).
Change in prothrombin time
The peak PT was noted on day 3 in all the three groups. By
day 30, no donor had a PT above the reference range. There was no
difference in PT between the groups.
The factors predicting the day 1 blood level, residual left
liver percentage, BMI, age, blood loss and degree of steatosis were
evaluated using univariate analysis. For the multivariate regres-
sion model, only fatty change, remnant left liver percentage, BMI
and age were included (Table 2). Fatty change was found to have a
significant correlation with the ALT level (P = 0.03) but not with
the AST (P = 0.09) or the bilirubin levels (P = 0.24). The remnant
left liver volume was found to have a significant negative correla-
tion with AST (P = 0.005) and ALT (P = 0.03) levels. BMI showed
a positive correlation with all three parameters.
Factors predicting steatosis
Further analysis was performed on factors predicting steatosis. In
univariate analysis, BMI, age, gender, and pre-operative levels of
AST, ALT, bilirubin and gamma-glutamyl transpeptidase (GGT)
Figure 1 Post-operative alanine aminotransferase (ALT) level (significant P-values are shown at reference points where median ALT levels are
compared with those of non-steatotic donors)
Figure 2 Post-operative aspartate aminotransferase (AST) level (significant P -values are shown at reference points where median AST levels
are compared with those of non-steatotic donors. *Pre-operative AST level: 10% steatosis, P = 0.001; >10% steatosis, P < 0.001)
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were analysed. For multivariate logistic regression models, signifi-
cant factors including BMI and levels of ALT and GGT were
included. Only BMI showed a significant correlation [P < 0.0001,
odds ratio (OR) = 1.47, confidence interval (CI) = 1.3–1.6] with
steatosis. The distribution of steatosis within four quartiles of
BMI is shown in Fig. 4. Seventy-five per cent of the donors in the
forth quartile of BMI (23.48–29 kg/m2) had steatosis. Seventy
per cent of donors who had >10% steatosis were in this category
(Fig. 5). A receiver-operating characteristic (ROC) curve showed
that the area under the curve for BMI on predicting steatosis was
0.75 (CI = 69–80). When all donors were considered together, a
BMI > 23.5 kg/m2 had a sensitivity of 45% (CI = 37–54) and
specificity of 90% (CI = 84–93), and a positive predictive value
of 77% (CI = 66–86) and negative predictive value of 64% (CI =
58–70) in predicting steatosis. Data of the 80 donors with BMI >
23.5 kg/m2 were further analysed separately for factors predicting
steatosis. For the multivariate regression model, age and pre-
operative levels of AST, ALT, bilirubin, and GGT were included.
Only ALT level showed a significant correlation with steatosis
(P = 0.05, OR = 1.14, CI = 1–1.3).
Donor morbidity
In G0, 17% (30/178) of the donors developed post-operative com-
plications. Most of them (23/30) had minor complications. In G1,
20% (26/128) of the donors developed post-operative complica-
tions. Among them, 22 had minor complications. In G2, 38%
(7/18) of the donors had post-operative complications. Compared
with G0, the overall incidence of complication was higher in the
other groups (P = 0.049). In these seven donors, one developed
post-operative bleeding, three had minor wound infections, two
had prolonged cholestasis that did not need any special treatment
and one had urinary tract infection.
Discussion
The present study showed that a transient increase in AST, ALT
and bilirubin levels occurred dependent on the degree of steatosis
of the donors. Few authors have looked into the patterns of
changes in liver enzymes after a hepatectomy in liver donors
with hepatic steatosis. Nagai et al.,9 analysing 46 donors who had
undergone a right hepatectomy, showed that there was significant
elevation in bilirubin and GGT levels in mildly (10%) steatotic
donors but the rise in ALT and AST levels were not significant.
However, their sample size was small, with only 10 donors having
steatosis. In a similar study, significant differences in AST, ALT and
bilirubin levels were noted in the initial post-operative period.8 In
two Doppler studies on steatotic livers, a significant reduction in
microcirculation in steatotic whole liver grafts was demonstrated,
which was largely attributed to a reduction in hepatic sinusoidal
space volume.11,12 Reduced microcirculation and increased sus-
ceptibility of steatotic hepatocytes to ischemia–reperfusion injury
Figure 3 Post-operative bilirubin level (significant P -value is shown at reference points where the median bilirubin level is compared with that
of non-steatotic donors)
Table 2 Multivariate analysis of factors affecting day 1 ALT, AST and
bilirubin levels
ALT AST Bilirubin
b P B P b P
Steatosis 0.12 0.03 0.09 0.24
Remnant left liver % -0.12 0.03 -0.155 0.005 0.6
BMI 0.19 0.001 0.18 0.001 0.13 0.02
Age 0.15 0.005 0.13 0.02 0.06
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI,
body mass index.
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Figure 4 Distribution of 325 donors in four quartiles of body mass
index (BMI) according to degree of steatosis
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have been attributed as the main factors leading to hepatic paren-
chymal injury in patients with a fatty liver. Our larger sample of
patients is unique. All of the grafts contained the MHV. Segment
IV congestion was a major concern in patients when the technique
was first introduced, but over the years our results have confirmed
the safety of the technique.7 Parenchymal congestion, the main
concern with a fatty liver, could be theoretically worsened when
the MHV is taken with the graft. The present study showed that
donors having < = 20% steatosis had only a transient rise in
enzyme levels. This is not different from previously documented
results with other types of graft.
The most accurate method of checking for hepatic steatosis is a
liver biopsy. Nonetheless, it is invasive and carries a risk of
approximately 0.05%.13 Considering that donors are healthy indi-
viduals, many centres, including the present, perform a biopsy
selectively. Numerous imaging modalities have been evaluated for
the prediction of degree of steatosis, but none is yet to be firmly
established.14 It is therefore important to predict which individu-
als will benefit from a liver biopsy. Rinella et al.15 proposed per-
forming a routine biopsy for Caucasian donors having a BMI
>28 kg/m2. However, for Asians, who have lower BMIs, the figure
needs to be adjusted. Peng et al.,16 studying 105 Asian living
donors, reported a higher likelihood of steatosis when a BMI was
>23 kg/m2. The present study showed that 70% of the donors
having a BMI >23.5 kg/m2 were steatotic (Fig. 5). If a biopsy is to
be offered selectively, a BMI of 23.5 kg/m2 could be used as a guide
in decision-making for Asian donors. Although a BMI cut-off of
23.5 kg/m2 has low sensitivity (45%), its specificity (90%) and
positive predictive value (77%) are high. The present centre accept
steatosis of up to 20%. Five donors in the present study had >20%
steatosis but they did not show any pre-operative indications.
Thus, a selective approach to a liver biopsy may still miss a small
percentage of donors with significant steatosis.
Over the 10-year study period, assessments of specimens
were performed under the supervision of one chief pathologist.
However, specimens were not routinely evaluated by two exam-
iners. The classification of fatty livers as no fatty change, up to
10% steatosis and more than 10% steatosis is an arbitrary division.
However, the present clinical and biochemical results support that
a liver with up to 20% steatosis can be used in right liver donation
even if the MHV is included in the graft.
The value of hepatic parenchymal enzyme levels has been
reported previously in the literature. Nagai et al.9 reported signifi-
cant differences in enzyme levels between steatotic and non-
steatotic liver donors. However, other authors reported a trend
towards an increase only.15 In our present study, although the
difference in the ALT level was significant, the factor itself was a
poor predictor of steatosis.
In summary, using a liver with up to 20% steatosis in a right
liver donation, even if the MHV is included in the graft, is safe. For
Asian donors, a BMI of 23.5 kg/m2 should be used as an important
guide in deciding whether to perform a liver biopsy, although this
selective approach may occasionally miss a donor with significant
steatosis.
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